Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study.

ABSTRACT:

Background

To confirm the feasibility and explore the clinical applicability of amplicon sequencing by next generation sequencing (NGS) of biopsy samples from patients with advanced solid tumors, we conducted a prospective study.

Methods

Patients with unresectable, advanced, or recurrent solid tumors were included. Key eligibility criteria were as follows: 20 years or older, any planned systemic therapy, adequate lesion for biopsy, and written informed consent. Samples were fixed in 10% buffered formalin and embedded in paraffin. Cancer-derived DNA was extracted, and amplicon sequencing was performed using Ion AmpliseqTM Cancer Hotspot Panel version 1.0 or version 2.0 by central vendor. We evaluated the success rate of sequencing, and the proportion of the patients with acti

SUBMITTER: Naito Y 

PROVIDER: S-EPMC5974784 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature